We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Glenmark’s Antiviral Drug Favipiravir Boosts Recovery Time of COVID-19 Patients in Phase 3 Study

By HospiMedica International staff writers
Posted on 24 Jul 2020
Print article
Image: Glenmark’s Antiviral Drug Favipiravir (Photo courtesy of Glenmark Pharmaceuticals Ltd.)
Image: Glenmark’s Antiviral Drug Favipiravir (Photo courtesy of Glenmark Pharmaceuticals Ltd.)
A phase 3 trial conducted by Glenmark Pharmaceuticals Ltd. (Mumbai, India) has demonstrated statistically significant faster time to clinical improvement with favipiravir treatment in mild to moderate COVID 19 patients compared to control.

Favipiravir is a broad spectrum oral antiviral drug that selectively inhibits RNA-dependent RNA polymerase (RdRp) and the viral replication phase of SARS-CoV-2, and is being studied in multiple ongoing international clinical trials. Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections and was granted approval in Russia for treatment of COVID-19 in May. It is being prescribed to patients in multiple countries across the globe under compassionate use for the treatment of COVID-19 infection. It also is being tested in close to 20 clinical trials across 3000+ COVID-19 patients globally, including ongoing clinical trials in the US, Canada, Japan and Italy.

Glenmark conducted an open-label randomized, multicenter clinical trial in 150 patients for evaluating the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19. Patients in the Glenmark Favipiravir clinical trial received Favipiravir tablets 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, along with standard supportive care. Randomization was stratified based on disease severity into mild (90 patients) and moderate (60 patients). Results from the Phase 3 trial showed numerical improvements for the primary efficacy endpoint with 28.6% faster viral clearance in the overall population as measured by the median time until cessation of oral shedding of virus in the Favipiravir treatment arm compared to those in the control arm.

Among the key secondary outcome measures for clinical improvement that demonstrated the efficacy and benefit of Favipiravir treatment arm over the control arm was a 40% faster achievement of "clinical cure" defined as the physician's assessment of normalization of clinical signs - temperature, oxygen saturation, respiratory rate and cough with a statistically significant reduction in median time to clinical cure in the Favipiravir treatment arm, compared to the control arm. 69.8% of patients in the Favipiravir treatment arm achieved clinical cure by Day 4, which was statistically significant compared to 44.9% observed in the control arm. Amongst patients who clinically deteriorated and required oxygen support, those receiving Favipiravir had a longer median time to first time use of oxygen of five days versus two days in the control arm.

Additionally, Glenmark's Favipiravir was well tolerated with no serious adverse events (SAEs) or deaths in the Favipiravir treated arm. One SAE occurred in the control arm and resulted in death due to worsening clinical disease and acute respiratory distress syndrome (ARDS) attributed to COVID-19 infection. Adverse events (AEs) were reported in 26 patients in the favipiravir treatment arm (35.6%) as compared to six patients in the control arm (8%) however, most AEs were mild to moderate and none led to drug discontinuation or dosing adjustments. The most commonly observed AE was asymptomatic transient increases in uric acid (12 patients in the Favipiravir treatment arm and zero in the control arm); most resolved on first follow up. Gastrointestinal disturbance was minimal and no clinically significant differences were observed between the treatment groups. Glenmark now plans to submit the clinical trial data for publication in a peer-reviewed journal in the coming weeks and share the findings.

“The results of the Indian Favipiravir study are encouraging. The trial was performed with a sense of urgency considering the gravity of the pandemic, yet scientific principles were not sacrificed,” said Dr. Zarir Udwadia, one of the Principal Investigators of this study. “I have had a chance to independently view the initial results and they are encouraging: Patients randomized to Favipiravir seemed to have faster clinical cure, and more importantly, faster viral clearance than those randomized to the routine care group. I eagerly await the final analysis and results from other ongoing studies from across the globe. Till then, I feel we have enough evidence to consider using Favipiravir in symptomatic COVID-19 patients who have mild to moderate infection.”

“We are encouraged with the top-line results and these indicate that early treatment with favipiravir may improve clinical outcomes for mild to moderate patients and could potentially prevent patients from progressing to ARDS and mortality,” said Dr. Monika Tandon, Vice President & Head - Clinical Development, Global Specialty/Branded Portfolio.


Related Links:
Glenmark Pharmaceuticals Ltd.

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Hospital Bed
Progressa Smart+

Print article
Detecto

Channels

Critical Care

view channel
Image: Vascular flow modeling exemplar; intracranial aneurysm flow, treatment and thrombosis (Photo courtesy of University of Leeds)

Faster, More Accurate Blood Flow Simulation to Revolutionize Treatment of Vascular Diseases

The field of vascular flow modeling is vital for understanding and treating vascular diseases, but traditionally, these methods require extensive labor and computation. Now, researchers have made groundbreaking... Read more

Surgical Techniques

view channel
Image: The prototype pacemaker is made of a specially engineered membrane (Photo courtesy of University of Chicago)

Ultra-Thin, Light-Controlled Pacemaker Regulates Heartbeats

Millions of individuals depend on pacemakers, small yet vital devices that help maintain a regular heartbeat by regulating the heart's electrical impulses. To minimize complications, there is growing interest... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.